Cargando…
Negative trials in ovarian cancer: is there such a thing as too much optimism?
Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990052/ https://www.ncbi.nlm.nih.gov/pubmed/27594913 http://dx.doi.org/10.3332/ecancer.2016.ed58 |
_version_ | 1782448635258077184 |
---|---|
author | Gyawali, Bishal Prasad, Vinay |
author_facet | Gyawali, Bishal Prasad, Vinay |
author_sort | Gyawali, Bishal |
collection | PubMed |
description | Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal. We also appeal against conducting large phase 3 trials that require significant resources without good phase 2 evidence for doing so. |
format | Online Article Text |
id | pubmed-4990052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-49900522016-09-02 Negative trials in ovarian cancer: is there such a thing as too much optimism? Gyawali, Bishal Prasad, Vinay Ecancermedicalscience Editorial Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal. We also appeal against conducting large phase 3 trials that require significant resources without good phase 2 evidence for doing so. Cancer Intelligence 2016-08-17 /pmc/articles/PMC4990052/ /pubmed/27594913 http://dx.doi.org/10.3332/ecancer.2016.ed58 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial Gyawali, Bishal Prasad, Vinay Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title_full | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title_fullStr | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title_full_unstemmed | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title_short | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
title_sort | negative trials in ovarian cancer: is there such a thing as too much optimism? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990052/ https://www.ncbi.nlm.nih.gov/pubmed/27594913 http://dx.doi.org/10.3332/ecancer.2016.ed58 |
work_keys_str_mv | AT gyawalibishal negativetrialsinovariancanceristheresuchathingastoomuchoptimism AT prasadvinay negativetrialsinovariancanceristheresuchathingastoomuchoptimism |